Imaging the Nigrostriatal Pathway in Patients with Idiopathic Normal Pressure Hydrocephalus and Parkinsonism
Objective: To investigate the nigrostriatal pathway in iNPH patients with clinical parkinsonism, employing dopaminergic transporter (DAT) and nigrosome imaging. Background: Patients with idiopathic Normal Pressure…Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium
Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…Tremulous Machado-Joseph Disease
Objective: To describe a case of spinocerebellar ataxia type 3 (SCA3) presenting with tremor. Background: Tremor is not a frequent manifestation in SCA3, especially as…Brain first-body first: is the dat-scan useful?
Objective: The purpose of this study is to evaluate possible differences in the DAT-SCAN ratios in patients with and without dysautonomia and RBD at diagnosis.…Premenstrual worsening of UPDRS motor scale in women affected by Parkinson’s Disease
Objective: The role of estrogen in dopaminergic pathways and the premenstrual worsening of parkinsonian symptoms. Background: Female sex hormones, during the menstrual cycle, could influence…Asymmetric and profound nigrostriatal dopaminergic dysfunction in Parkinson’s disease with preceding REM sleep behavior disorders
Objective: To investigate the differences in the pattern of nigrostriatal and pontine monoaminergic degeneration patients with de novo Parkinson's disease (PD), stratified by the presence…Evoking Parkinsonism in Mice by a Pharmacological Approach Combined with Targeted Viral-based Manipulations of Neuronal Ensembles
Objective: We implement a pharmacological approach for eliciting dopamine deprivation using transient blockage of dopamine signaling to replicate core parkinsonian motor symptoms. Background: Parkinson’s disease…Investigating the use of DAT-SPECT as an enrichment biomarker to determine eligibility for the phase 2 clinical trial PASADENA
Objective: Evaluate dopaminergic imaging DAT-SPECT as an enrichment strategy to avoid inclusion of participants with scans without evidence of dopaminergic deficit (SWEDD) in a Phase…Correlation between 3 Tesla Brain MRI Nigrosome-1 imaging and SPECT 123I-Ioflupane in parkinsonian disorders
Objective: To correlate nigrosome-1 (NG1) imaging and SPECT 123I-Ioflopane findings to determine the feasibility and diagnostic value of NG1 imaging in a real-world clinical setting.…Progression of nigro-striatal denervation in cerebellar Multiple System Atrophy: a prospective study
Objective: To study the progression of nigro-striatal denervation and evaluate the capacity for [123I]-FP-CIT-SPECT and parkinsonian signs to differentiate MSA-C from idiopathic late-onset cerebellar ataxia…
- 1
- 2
- 3
- …
- 5
- Next Page »